News | November 07, 2024
Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr
US Generics grew 5% to Rs. 467 Crores for the quarter
US Generics grew 5% to Rs. 467 Crores for the quarter
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Stable profits, low leverage to keep credit profiles comfortable
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
